Canada
· Delayed Price · Currency is CAD RAMM Pharma Statistics
Total Valuation
RAMM Pharma has a market cap or net worth of CAD 1.79 million. The enterprise value is 1.51 million.
| Market Cap | 1.79M |
| Enterprise Value | 1.51M |
Important Dates
The next estimated earnings date is Friday, June 27, 2025.
| Earnings Date | Jun 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RAMM Pharma has 119.39 million shares outstanding. The number of shares has decreased by -0.76% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 119.39M |
| Shares Change (YoY) | -0.76% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 27.52% |
| Owned by Institutions (%) | n/a |
| Float | 86.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.41 |
| PB Ratio | 0.14 |
| P/TBV Ratio | 0.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.10 |
| EV / Sales | 0.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.48 |
Financial Position
The company has a current ratio of 1.46, with a Debt / Equity ratio of 0.02.
| Current Ratio | 1.46 |
| Quick Ratio | 0.73 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.06 |
| Interest Coverage | -220.46 |
Financial Efficiency
Return on equity (ROE) is -75.84% and return on invested capital (ROIC) is -26.66%.
| Return on Equity (ROE) | -75.84% |
| Return on Assets (ROA) | -23.67% |
| Return on Invested Capital (ROIC) | -26.66% |
| Return on Capital Employed (ROCE) | -69.44% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.19 |
| Inventory Turnover | 1.07 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -66.67% in the last 52 weeks. The beta is -0.01, so RAMM Pharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.01 |
| 52-Week Price Change | -66.67% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.02 |
| Relative Strength Index (RSI) | 36.92 |
| Average Volume (20 Days) | 13,500 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, RAMM Pharma had revenue of CAD 4.40 million and -15.23 million in losses. Loss per share was -0.13.
| Revenue | 4.40M |
| Gross Profit | 1.75M |
| Operating Income | -8.68M |
| Pretax Income | -15.31M |
| Net Income | -15.23M |
| EBITDA | -7.84M |
| EBIT | -8.68M |
| Loss Per Share | -0.13 |
Balance Sheet
The company has 480,436 in cash and 197,691 in debt, giving a net cash position of 282,745 or 0.00 per share.
| Cash & Cash Equivalents | 480,436 |
| Total Debt | 197,691 |
| Net Cash | 282,745 |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 12.43M |
| Book Value Per Share | 0.10 |
| Working Capital | 1.41M |
Cash Flow
In the last 12 months, operating cash flow was -3.06 million and capital expenditures -59,431, giving a free cash flow of -3.12 million.
| Operating Cash Flow | -3.06M |
| Capital Expenditures | -59,431 |
| Free Cash Flow | -3.12M |
| FCF Per Share | -0.03 |
Margins
| Gross Margin | 39.79% |
| Operating Margin | -197.50% |
| Pretax Margin | -348.30% |
| Profit Margin | n/a |
| EBITDA Margin | -178.23% |
| EBIT Margin | -197.50% |
| FCF Margin | n/a |
Dividends & Yields
RAMM Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.76% |
| Shareholder Yield | 0.76% |
| Earnings Yield | -850.60% |
| FCF Yield | -174.27% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RAMM Pharma has an Altman Z-Score of -6.93. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.93 |
| Piotroski F-Score | n/a |